文献速递银屑病与炎症性皮肤病

Toll样受体介导的CXCL16上调在银屑病中协调中性粒细胞活化

Toll-Like Receptor-Mediated Upregulation of CXCL16 in Psoriasis Orchestrates Neutrophil Activation.
PubMed 文献 · J Invest Dermatol · 2017-09-20

该研究探讨先天免疫刺激如何通过Toll样受体(TLR)上调CXCL16并促进中性粒细胞浸润。刺激角质形成细胞、单核细胞和树突状细胞后CXCL16表面表达和分泌增强,CXCL16可降低中性粒细胞硬度、促进迁移并增强IL-8趋化效应,TNF-α阻断剂治疗可抑制CXCL16表达,提示CXCL16是银屑病潜在治疗靶点。

要点

  • TLR1/2、2/6、7配体及I型干扰素可上调CXCL16表达和分泌。
  • CXCL16降低中性粒细胞硬度并增强IL-8趋化作用,促进透血管迁移。
  • TNF-α阻断剂有效治疗可抑制CXCL16表达,支持其致病作用。

核心结论

  • 先天免疫刺激通过TLR上调CXCL16,进而促进中性粒细胞活化和浸润皮肤,CXCL16可能是银屑病未来治疗靶点。

研究设计与样本

  • 体外刺激角质形成细胞、单核细胞和树突状细胞,使用I型干扰素或TLR1/2、2/6、7配体。
  • 采用实时形变细胞术检测中性粒细胞力学特性,并评估CXCL16对中性粒细胞迁移的影响。
  • 观察银屑病患者经TNF-α阻断剂有效治疗后CXCL16表达变化。

主要发现

  • TLR1/2、2/6、7配体及I型干扰素刺激后CXCL16表面表达和分泌增强,而TLR7/8刺激未增强。
  • CXCL16和IL-8降低中性粒细胞硬度并增强形变,促进其穿越血管壁。
  • CXCL16可诱导中性粒细胞迁移并增强IL-8趋化效应,IL-8可增强中性粒细胞产生CXCL16,形成正反馈环路。
  • 银屑病患者经TNF-α阻断剂有效治疗后CXCL16表达被阻断。

临床怎么用

  • CXCL16及其受体CXCR6可能成为银屑病治疗的新靶点,尤其针对早期中性粒细胞浸润环节。
  • TNF-α阻断剂治疗可抑制CXCL16表达,提示其疗效部分通过该通路介导。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Innate immune processes are central in the development of the chronic inflammatory skin disease psoriasis. Studying stimulation of keratinocytes, monocytes, and dendritic cells by type I interferons or ligation of Toll-like receptors 1/2, 2/6, or 7, but not 7/8, resulted in enhanced surface expression and secretion of CXC chemokine ligand (CXCL) 16. The corresponding CXC chemokine receptor 6 was expressed on neutrophils whose recruitment into skin is important, especially in early psoriatic disease. Using the recently developed technique real-time deformability cytometry demonstrated that CXCL16 and IL-8 decreased the stiffness and enhanced deformation of neutrophils facilitating transmigration through vessel wall. In addition, CXCL16 potently induced migration of neutrophils and enhanced the chemotactic effect of IL-8. The positive feedback loop was supported by IL-8 enhancing CXCL16 production of neutrophils. Blocking of CXCL16 expression by effective treatment of psoriasis patients with tumor necrosis factor-α blockers further supported the pathogenic role of this chemokine. In summary, the data link innate immune stimulation to CXCL16 upregulation and neutrophil infiltration into skin. CXCL16 could therefore represent a potent future target for treatment of psoriasis.

来源:J Invest Dermatol,查看原文。版权归原作者所有。

引用

  1. Steffen S, Abraham S, Herbig M, et al. Toll-Like Receptor-Mediated Upregulation of CXCL16 in Psoriasis Orchestrates Neutrophil Activation. J Invest Dermatol. 2017. PMID: 28942364. doi:10.1016/j.jid.2017.08.041

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。